SARASOTA, Fla., June 02, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced fiscal year 2025 financial results. FY2025 Financial Highlights (all metrics compared to FY2024 unless otherwise noted) Revenue was $6,841,250, an increase of 5% compared to $6,532,000. Consolidated clinic revenue increased 4% to $6,721,057, compared to $6,450,431. Revenue from all clinics was $8,021,929, including both consolidated and equity method clinics, an increase of 4% compared to $7,731,177. Net loss from continuing operations was $(5.3) million compared to $(7.7) million. Adjusted EBITDA (see table included) was $(3.2) million compared to $(2.2) million. Recent Highlights Financing and Balance Sheet Strengthening : The Company announced financing transactions in December 2025 ($4 million) and January 2026 ($7.5 million) representing approximately $11.5 million of aggregate gross proceeds before expenses, providing additional flexibility to execute the Company's growth strategy and pay down certain liabilities. Further, as of March 31, 2026, all Series C-2 Preferred Stock had been converted or retired, warrant liabilities have been eliminated, and cash balances are higher, resulting in a further strengthening of the balance sheet and streamlined capitalization structure. After the first quarter 2026 financing and conversion of remaining Series C-2 Preferred Stock, the total common shares outstanding as of June 2, 2026 is approximately 1.8 million shares. Indiana Expansion : The Company successfully closed the acquisition of Indiana-based Family Beginnings in February 2026, adding a fourth operational fertility clinic in the United States and expanding the Company's Midwest presence. Family Beginnings generated approximately $1.2 million in revenue and approximately $0.2 million in net income for the trailing twelve-month period ended September 30, 2025. Employer-benefit Access Expansion : Wisconsin Fertility Institute joined the Progyny network, broadening access to employer-sponsored patients and strengthening the Company's payor mix. Innovation and Intellectual Property : The Company continued investing in technology and platform differentiation through issuance of a new patent for its modified INVOcell device, extending protection through 2040. Advanced Laboratory Innovation : The Company announced the availability of time-lapse incubation technology at the Wisconsin Fertility Institute, adding an advanced embryo monitoring solution intended to support informed clinical decision-making and enhance patient engagement, reinforcing the Company’s commitment to quality, innovation, and patient-centered fertility care. Strengthened Operations Team: INVO is strengthening its operations through the addition of key support personnel with deep clinical operations experience to drive organizational growth, optimize day-to-day clinic performance, and support consistent, patient-centered care across INVO Fertility clinics. New Organic Growth Initiatives: Starting in March 2026, the Company implemented a series of organic growth initiatives at its Atlanta clinic which are having meaningful impact. Strategic Outlook Over the past year, INVO Fertility has taken meaningful steps to simplify and strengthen its capital structure. Management believes the Company's balance sheet is the strongest it has been in more than three years, providing additional optionality to pursue acquisitions from a position of strength, invest in organic growth initiatives, and navigate the market with greater confidence. The Company believes fertility care remains supported by favorable long-term demand trends, expanding employer-benefit coverage, increased public awareness around access to care, and a more supportive environment for IVF. INVO's strategic priorities are centered on driving organic growth across its existing clinics, integrating and expanding Family Beginnings, pursuing disciplined acquisitions that can enhance long-term earnings power, and continuing to expand the commercial and intellectual property value of the INVOcell platform. Management Commentary "This past year marked an important transition for INVO Fertility marked by meaningful progress across operations, acquisitions, and capital structure, positioning the Company for growth through both organic initiatives and strategic clinic acquisitions moving forward," commented Steve Shum, CEO of INVO Fertility. "We believe the business has now moved beyond stabilization and into a higher-growth phase. The financing actions completed around year-end and early 2026 improved our flexibility and clarity of capital structure, while the closing of the Family Beginnings acquisition expanded our clinic network to four operational fertility clinics. At the same time, we continue to see attract